AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (213.3 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter | Open Access

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy

Hui Luo1,2,*, Tongjuan Li1,2,*, Fankai Meng1,2, Zhenya Hong1,2, Yang Cao1,2, Gaoxiang Wang1,2, Liang Huang1,2, Xiaoxi Zhou1,2 ( )
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan 430030, China

*These authors contributed equally to this work.

Show Author Information

Electronic Supplementary Material

Download File(s)
cbm-22-5-496_ESM.pdf (388.9 KB)

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Biology & Medicine
Volume 22 Issue 5,
May 2025
Pages 496-501
DOI: 10.20892/j.issn.2095-3941.2024.0626

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Luo H, Li T, Meng F, et al. CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy. Cancer Biology & Medicine, 2025, 22(5): 496-501. https://doi.org/10.20892/j.issn.2095-3941.2024.0626

408

Views

37

Downloads

1

Crossref

4

Web of Science

2

Scopus
Received: 31 December 2024
Accepted: 14 March 2025
Published: 06 May 2025
©2025 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License